Xilio Therapeutics, Inc. (XLO)
XLO Stock Price Chart
Explore Xilio Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze XLO price movements and trends.
XLO Company Profile
Discover essential business fundamentals and corporate details for Xilio Therapeutics, Inc. (XLO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Oct 2021
Employees
64.00
Website
https://www.xiliotx.comCEO
Rene Russo
Description
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
XLO Financial Timeline
Browse a chronological timeline of Xilio Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.59, while revenue estimate is $12.72m.
Earnings released on 12 May 2026
EPS came in at -$0.58 surpassing the estimated -$0.66 by +12.12%, while revenue for the quarter reached $12.65m , beating expectations by +48.47%.
Earnings released on 23 Mar 2026
EPS came in at -$0.85 surpassing the estimated -$1.68 by +49.40%, while revenue for the quarter reached $13.69m , beating expectations by +25.60%.
Stock split effective on 16 Mar 2026
Shares were split 1 : 14 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2025
EPS came in at -$0.03 surpassing the estimated -$0.45 by +93.28%, while revenue for the quarter reached $19.07m , beating expectations by +2.31%.
Earnings released on 14 Aug 2025
EPS came in at -$0.16 surpassing the estimated -$1.10 by +85.50%, while revenue for the quarter reached $8.08m , missing expectations by -56.62%.
Earnings released on 8 May 2025
EPS came in at -$0.18 surpassing the estimated -$2.70 by +93.33%, while revenue for the quarter reached $2.93m , missing expectations by -87.37%.
Earnings released on 11 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$3.03 by +93.41%, while revenue for the quarter reached $1.72m , missing expectations by -92.57%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $2.26m , missing expectations by -31.42%.
Earnings released on 8 Aug 2024
EPS came in at -$0.24 falling short of the estimated -$0.23 by -4.35%, while revenue for the quarter reached $2.36m , missing expectations by -92.14%.
Earnings released on 14 May 2024
EPS came in at -$0.62 falling short of the estimated -$0.11 by -463.64%.
Earnings released on 1 Apr 2024
EPS came in at -$0.64 matching the estimated -$0.64.
Earnings released on 9 Nov 2023
EPS came in at -$0.61 surpassing the estimated -$0.81 by +24.69%.
Earnings released on 14 Aug 2023
EPS came in at -$0.70 surpassing the estimated -$0.87 by +19.54%.
Earnings released on 9 May 2023
EPS came in at -$0.83 surpassing the estimated -$0.89 by +6.74%.
Earnings released on 2 Mar 2023
EPS came in at -$0.82 falling short of the estimated -$0.78 by -5.13%.
Earnings released on 9 Nov 2022
EPS came in at -$0.72 surpassing the estimated -$0.88 by +18.18%.
Earnings released on 9 Aug 2022
EPS came in at -$0.90 falling short of the estimated -$0.78 by -15.38%.
Earnings released on 12 May 2022
EPS came in at -$0.78 surpassing the estimated -$0.93 by +16.13%.
Earnings released on 1 Mar 2022
EPS came in at -$0.98 surpassing the estimated -$1.17 by +16.24%.
Earnings released on 2 Dec 2021
EPS came in at -$21.27 falling short of the estimated -$1.60 by -1.23k%.
XLO Stock Performance
Access detailed XLO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
